However, CaMKK2 inhibition may offer a significant improvement over androgen deprivation therapy as it not only prevents prostate cancer progression but also protects against metabolic syndrome, improves insulin sensitivity, and increases bone mass [5,64,84]. Here, INS is linked to prostate carcinoma.